Introduction {#s001}
============

C[linical biospecimens used]{.smallcaps} in research are subject to two types of laboratory analyses. The first of these is the analysis of established clinical biology/pathology parameters where reference ranges are usually known and methods are validated (e.g., CLIA or ISO15189 accreditation). Results of these analyses are necessary to support any research on novel clinically relevant biomarkers (definition of true positive and negative cases, use as a reference method). The second type is analysis of research parameters where there are usually no established reference ranges, and often methods are not validated by the laboratory as extensively as clinical biology/pathology methods.^[@B1]^ Results of these analyses are used to discover novel clinical endpoint correlates (biomarkers).

*In vivo* and *in vitro* pre-analytical variations have a more or less significant impact on the output of analyses, depending on the biospecimen type, the pre-analytical variable, and the analyte of interest. According to the type of analysis above, the word "significant" has a different meaning. In the first type---the analysis of clinical biology/pathology parameters---"significant" means clinically consequential at the diagnostic level. In the second type---analysis of research parameters---"significant" means statistically significant. Examples illustrating this concept are shown in [Table 1](#T1){ref-type="table"}.

###### 

[Examples Illustrating the Probable Impact of Pre-Analytical Conditions on the Analysis of Clinical or Research Parameters]{.smallcaps}

  *Pre-analytical condition*      *Biospecimen type*   *Analyzed parameter*                                                             *Probable impact on the output of analyses*
  ------------------------------- -------------------- -------------------------------------------------------------------------------- ---------------------------------------------
  Pre-centrifugation conditions   Serum                Clinical antibodies (e.g., anti-EBV IgG)                                         Non-significant (clinically)
  Pre-centrifugation conditions   Serum                Research cytokines (e.g., IL-8)                                                  Significant (statistically)
  Pre-centrifugation conditions   Citrate plasma       Research cytokines (e.g., IL-8)                                                  Non-significant (statistically)
  Pre-centrifugation conditions   Citrate plasma       Coagulation parameters (e.g., factor V, factor VIII)                             Significant (clinically)
  Formalin fixation time          Lung tissue          IHC clinical antibodies (e.g., CK7)                                              Non-significant (clinically)
  Formalin fixation time          Lung tissue          Mutation analysis by next-generation sequencing (e.g., allele frequency \<10%)   Significant (not detectable mutation)
  Alcohol fixation time           Lung tissue          Mutation analysis by next-generation sequencing (e.g., allele frequency \<10%)   Non-significant (detectable mutation)

CK7, cytokeratin 7; EBV, Epstein--Barr virus; IgG, immunoglobulin G; IHC, immunohistochemistry; IL8, interleukin 8.

In some cases, the impact may be molecule- and even epitope-specific, for example tissue ischemia time may influence specific phospho-epitopes differently. A standard biospecimen research experimental protocol has been proposed for this type of research.^[@B2]^

Therefore, in all research comparing different groups of samples for biomarker discovery, it is critical that all samples are of comparable quality to avoid the introduction of uncontrolled variables and increase the power of analysis of biomarkers. There are two approaches to this end: either sample collections with careful pre-analytical annotations (SPREC),^[@B3]^ or retrospective collections with appropriate quality control (QC) and sample qualification or quality stratification. A combination of the two approaches to control compliance of procedures with specified SPRECs is also possible.

Biobanks underpin all three layers of biomarker discovery, validation, and use in clinical practice. In the biomarker discovery phase, biospecimens collected and processed with one Standard Operating Procedure (SOP), and corresponding to one quality category, should be used in order to avoid pre-analytical bias and increase the power of research. However, in the biomarker validation phase, biospecimens collected and processed with more than one known and documented SOPs and corresponding to more than one quality category should be used in order to validate the robustness of a biomarker to relevant pre-analytical variations. Finally, in the biomarker clinical implementation phase, biospecimens collected and processed via validated SOPs should be used in order to ensure successful and accurate clinical diagnostic results. For these reasons, during recent years, biobank managers, auditors, and funding bodies have been asking what assays can be performed in order to assess the quality of biospecimens objectively. This technical review provides answers to this question. Although gaps exist, this review shows that many tools are already available and can be used for specimen qualification.

Methods {#s002}
=======

For the purposes of this technical report, the members of the International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group held face-to-face meetings and teleconferences between 2013 and 2015. The chair of the Working Group performed a thorough literature review and compiled a list of relevant and effective QC attributes for different categories of biospecimens. This list was reviewed and complemented by members of the Working Group. When the information is based on published evidence, the corresponding reference is given. When no reference is given, the information corresponds to current practice or to the corresponding author\'s opinion.

The following definitions were used: • *Biospecimen*: any biological specimen, which may be a:○ *Primary sample*: specimen directly collected from the donor (e.g., whole blood, urine, solid tissue);○ *Simple derivative*: sample prepared through a simple laboratory manipulation (e.g., after centrifugation of collection tubes or mechanical disruption of tissues) without the addition of chemical substances, and without cell disruption or cell selection as part of a multi-step process; or○ *Complex derivative*: derivative whose isolation requires usage of multiple steps and/or addition of chemical substances (e.g., nucleic acids, proteins, lipids, sorted cells, cultured cells, immortalized cells).• *Qualification*: process of examination of a biospecimen or a collection of biospecimens, and verification, based on objective analytical evidence, of their suitability for research use, either in a specific disease area or on a specific downstream analytical platform.• *Quality stratification*: process of examination of a biospecimen or a collection of biospecimens, and their classification, based on objective analytical evidence, into distinct categories, each category corresponding to a specific *in vivo* biological characteristic (e.g., level of inflammation, % tumor, protein content) or to a specific *ex vivo* pre-analytical condition (e.g., pre-centrifugation conditions).• *Biomolecular integrity*: quality status of a biospecimen, reflecting whether biomolecules of interest have not undergone either statistically or clinically significant changes relative to their *in vivo* state/levels.• *Commutability*: equivalence of analytical methods, based on objective evidence.

The term "qualification" is used qualitatively. Therefore, a biospecimen is or is not qualified for use in research in a specific disease area or on a specific analytical platform.

The term "quality stratification" is used quantitatively. Therefore, one or more thresholds apply in order to stratify biospecimens in two or more quality categories. These quality categories correspond to defined *in vivo* or *in vitro* conditions.

When qualification is not possible because of lack of relevant assays, then quality stratification can be made. In some cases, qualification can be achieved for biomarker research in a specific disease area ([Table 2](#T2){ref-type="table"}) or on a specific downstream analytical platform. For primary samples, qualification depends on their biomolecular integrity. For simple or complex derivatives, qualification depends both on the biomolecular integrity of the primary sample from which the derivative has been extracted and on the efficiency/performance of the extraction, culture, cryopreservation, or other laboratory manipulation (e.g., cfDNA from plasma; [Fig. 1](#f1){ref-type="fig"}).

![Flow diagram illustrating sample preparation and qualification for use in research.](fig-1){#f1}

###### 

[QC Measurands for Qualification for Use in Specific Disease Areas]{.smallcaps}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Biospecimen type*                                  *Measurand*                                                              *Scope of qualification (disease area)*   *Measurement method*
  --------------------------------------------------- ------------------------------------------------------------------------ ----------------------------------------- ----------------------------
  Serum                                               Brain natriuretic peptide (BNP), NT-proBNP^[@B6]^\                       Cardiovascular                            EIA\
                                                      Angiopoietin-like 3 (ANFPTL3)\                                                                                     ECLIA/EIA\
                                                      Creatinine kinase MB isoenzyme (CK-MB)\                                                                            EIA
                                                      Endothelin 1 (ET-1)                                                                                                

  Heparin plasma, serum                               Matrix metalloproteinase-3 (MMP-3), matrix metalloproteinase-9 (MMP-9)                                             EIA

  All plasma,^[a](#tf2){ref-type="table-fn"}^ serum   Troponin I & T                                                                                                     ECLIA/EIA

  All plasma                                          Vasoactive intestinal peptide (VIP)                                                                                EIA

  All plasma                                          Cholesterol ester transfer protein activity (CETP)                       Lipid metabolism                          Fluoroimmunoassay

  Serum                                               Alanine aminotransferase (ALT)^[@B7]^                                    Liver                                     Enzymatic assay

  Serum, all plasma                                   Tumor necrosis factor alpha (TNF-α)                                      Autoimmune, inflammatory                  Sensitive EIA

  Serum                                               Insulin C peptide^[@B8]^\                                                Endocrinology and diabetes                Fluoroimmunoassay, EIA/RIA
                                                      Insulin-like growth factor II precursor                                                                            

  All plasma                                          Glucagon-like peptide 1 (cleared by DPP4)^[@B9]^                                                                   EIA/RIA

                                                      Adenocorticotrophic hormone (ACTH)                                                                                 ECLIA/RIA

  All plasma, serum                                   Aldosterone\                                                                                                       EIA
                                                      Somatomedin C                                                                                                      

  Citrate plasma                                      Anti-factor Xa\                                                          Coagulation                               Clot detection
                                                      Fibrinogen                                                                                                         

                                                      Prothrombin fragments 1&2\                                                                                         EIA
                                                      Plasminogen activator inhibitor type 1 activity or antigen                                                         

                                                      Thrombin generation assay                                                                                          Fluoroimmunoassay

                                                      Tissue-type plasminogen activator antigen (TPA antigen)                                                            EIA

  Urine                                               Beta 2 microglobulin                                                     Nephrology                                Nephelometry, EIA/RIA

  All plasma, serum                                   Complement C3                                                            Inflammation, immunology                  Nepholometry, EIA

  All plasma, serum                                   Intercellular adhesion molecule 1 (ICAM-1)                                                                         EIA

  Citrate/heparin plasma, serum                       TNF-α                                                                                                              EIA

  Serum                                               M65 EpiDeath                                                             Oncology                                  EIA

  Heparin plasma, serum                               Vascular adhesion molecule I (VCAM-1)                                                                              EIA

  Serum                                               Mid-osteocalcin, osteocalcin, calcitonin                                 Musculoskeletal                           ECLIA, EIA

                                                      Parathyroid hormone, intact (PTH)                                                                                  ECLIA, EIA

  All plasma, serum                                   Telopeptide C terminal, type 1 collagen                                                                            ECLIA, EIA

  Serum                                               Vitamin B12                                                              Nutritional                               ECLIA

  CSF, serum, all plasma                              Amyloid Ab42                                                             Neurodegenerative                         EIA

  Serum, CSF                                          Neuron-specific enolase^[@B10]^                                                                                    Kryptor immunoassay, EIA
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All plasma refers to all EDTA, citrate, and heparinized plasma.

CSF, cerebrospinal fluid; DPP4, dipeptidylpeptidase 4; ECLIA, electrochemiluminescent immunoassay; EIA, enzyme immunoassay; QC, quality control; RIA, radioimmunoassay.

Results {#s003}
=======

The results are presented in the form of Tables for fluid ([Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}), tissue ([Tables 5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}), and cytological biospecimens and their derivatives.

###### 

[QC Measurands for Qualification of Fluid Biospecimens and Their Derivatives]{.smallcaps}

  *Biospecimen type*     *Qualification parameter*         *Measurand*                                                                                                                                                                                                         *Scope of qualification*   *Measurement method*
  ---------------------- --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- ------------------------------
  Cf DNA                 Contamination by blood cell DNA   DNA fragment size 100--300 bp^[@B11]^                                                                                                                                                                               Cf DNA genotyping          Microfluidic electrophoresis
  Cf miRNA               Extraction efficiency             Spike in miRNA control ([www.qiagen.com/lu/resources/resourcedetail?id=710c0168-e408-408b-95af-91df5b5b1dd6&lang=en](www.qiagen.com/lu/resources/resourcedetail?id=710c0168-e408-408b-95af-91df5b5b1dd6&lang=en))   Cf miRNA analysis          qRT PCR
                                                           miRNA 16 or other ubiquitous miRNA target                                                                                                                                                                           Cf miRNA analysis          qRT PCR
  Stool DNA              Inhibitors                        SPUD^[@B12]^                                                                                                                                                                                                        PCR applications           qPCR
                         Extraction efficiency             Bacterial DNA content                                                                                                                                                                                               Bacterial DNA analysis     qPCR
                                                           Human DNA content                                                                                                                                                                                                   Human DNA analysis         qPCR
  Whole-blood cell DNA   Inhibitors                        SPUD^[@B12]^                                                                                                                                                                                                        PCR applications           qPCR

Cf, cell free; qRT PCR, quantitative reverse transcription polymerase chain reaction.

###### 

[QC Measurands for Quality Stratification of Fluid Biospecimens and Their Derivatives]{.smallcaps}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Biospecimen type*                           *Quality stratification parameter*            *Quality stratification parameter category*          *Measurand*                                                         *Quality stratification threshold*   *Measurement method and reference*
  -------------------------------------------- --------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------- ------------------------------------ ---------------------------------------------------------------------------------------------------------------------------
  Serum                                        Pre-centrifugation conditions                 \>8 h 4°C                                            Transferrin receptor                                                \>300 IU/mL                          ELISA^[@B13]^

                                               Post-centrifugation conditions                \>24 h RT                                            sCD40L                                                              \<4 ng/mL                            ELISA^[@B14]^

                                               Coagulation conditions                        Not effectively coagulated                           Fibrinogen                                                          \>100 mg/mL                          ELISA

                                               Hemolysis                                     Hb contaminated                                      Hb                                                                  \>50 mg/L                            ELISA, spectrophotometry ([www.ifcc.org/ifccfiles/docs/130401002end.pdf](www.ifcc.org/ifccfiles/docs/130401002end.pdf))

                                               Inflammation                                  Inflamed                                             C-reactive protein (CRP)                                            \>10 mg/L                            Nephelometry, ELISA

  Rapid serum (RST)                            Pre-centrifugation conditions                 \>48 h 4°C                                           Progastrin-releasing peptide (proGRP)                               \<30 pg/mL                           Architect instrument^[@B15]^

  EDTA plasma                                  Pre-centrifugation conditions                 \<3 h RT\                                            Lacascore\                                                          \<5\                                 Enzymatic assays^[@B16]^\
                                                                                             \<2 h, 2--6 h, \>6 h RT                              Metanomics                                                          MxP score ≥90, 89--70, \<70          GC MS^[@B17]^

                                               Post-centrifugation conditions                \>24 h RT                                            sCD40L                                                              \<0.3 ng/mL                          ELISA (Betsou, unpublished)

  All plasma^[a](#tf5){ref-type="table-fn"}^   Post-centrifugation conditions                \>4 h RT                                             Complement component 3 peptide (C3f), complement component 4 (C4)   C4,1896.1*m*/*z\                     MALDI-TOF-MS\
                                                                                                                                                                                                                      *C3f, 2021.1*m*/*z*                  LC-ESI-MS/^[@B18],[@B19]^

                                               Platelet contamination                        Platelet poor                                        Platelets                                                           \<10^4^/mL                           Cell count (<https://en.wikipedia.org/wiki/Platelet-poor_plasma>)

                                               Platelet activation                           Activated platelets                                  β-thromboglobulin (βTG)                                             \>200 ng/mL                          ELISA^[@B20]^

                                               Hemolysis                                     Hb contaminated                                      Hb                                                                  \>20 mg/L                            ELISA, spectrophotometry^[@B21]^ ([www.ifcc.org/ejifcc/vol13no4/13041002.htm](www.ifcc.org/ejifcc/vol13no4/13041002.htm))

                                               Inflammation                                  Inflamed                                             CRP                                                                 \>10 mg/L                            Nephelometry, ELISA

  Citrate plasma                               Pre-centrifugation conditions                 \>26 h 4°C                                           F VIII:C activity                                                   \<50 IU/dL                           Coagulation activity assay^[@B22]^

                                               Post-centrifugation conditions                \>9 years −80°C                                      Protein S activity                                                  \<50%                                Coagulation activity assay^[@B23]^

  Urine                                        Freezing                                      \>6 months −20°C                                     Alkaline phosphatase activity                                       \<0.1 IU/mmol creatinine             Enzymatic assay^[@B24]^

                                               Protein content                               Low, intermediate, high, very high protein content   Creatinine\                                                         10, 50, 100 mg/dL\                   ELISA^[@B25]^
                                                                                                                                                  Cystatin C                                                          10, 50, 100 ng/mL                    

                                               acidity                                       Alcaline                                             pH                                                                  \>8                                  pH paper

  CSF                                          Post-centrifugation conditions                \>32 h 4°C\                                          Transthyretin (TTR) isoforms\                                       Unmodified TTR-Cys10 peak \<60%\     ESI-MS^[@B26]^\
                                                                                             \>3 months −20°C                                     Cystatin C (CycC) truncation                                        Intact CycC\>truncated CysC peak     MALDI-TOF-MS, SELDI MS^[@B27],[@B28]^

                                               Hemolysis                                     Hb contaminated                                      Hb                                                                  \>15 ng/mL                           ELISA^[@B28]^

  Stool                                        Inflammation                                  Inflamed                                             Calprotectin                                                        \>50 mg/kg                           ELISA^[@B29]^

  Whole blood cell DNA                         Double-strandedness                           Highly double stranded                               Spectrofluorimetry                                                  \>70%                                Spectrophotometry, spectrofluorimetry

                                               Integrity                                     No degraded                                          MW                                                                  ≥30 kb                               Gel electrophoresis

                                                                                             With no strand breaks                                Long-range amplifiability                                           15 kb                                PCR

                                               Purity                                        Not protein contaminated                             A260/A280 ratio                                                     ≥1.5                                 Spectrophotometry

                                               Damage (oxidation, deamination, alkylation)   TBD                                                  Apurinic/apyrimidinc sites                                          TBD                                  Colorimetric detection (aldehyde reactive probe-based)

                                               Post-bisulfitation quality                    Of high DNA integrity                                PCR amplicon size                                                   ≥600 bp                              Multiplex PCR^[@B30]^

  Whole blood cell RNA                         rRNA integrity                                Of high integrity                                    RIN                                                                 \>7                                  Microfluidic electrophoresis

                                               mRNA integrity                                Not 5′ degraded                                      mRNA index                                                          \|ΔCt\|\<1                           qRT PCR^[@B31]^

                                               purity                                        Not protein contaminated                             A260/A280 ratio                                                     \>1.6                                Spectrophotometry

                                               Pre-centrifugation conditions                 \>24 h RT                                            Gene targets^[b](#tf6){ref-type="table-fn"}^                        TBD                                  qRT PCR^[@B32],[@B33]^

                                               WBC subpopulation composition                 Normal composition                                   Lymphocytes, granulocyte, monocyte numbers                          Neutrophils: 2.5--7.5 × 10^9^/L\     Blood count^[@B34]^ (<http://emedicine.medscape.com/article/2085133-overview>)
                                                                                                                                                                                                                      Lymphocytes: 1.5--3.5 × 10^9^/L\     
                                                                                                                                                                                                                      Monocytes: 0.2--0.8 × 10^9^/L        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All plasma refers to all EDTA, citrate, and heparinized plasma.

Under investigation by the International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group.

ELISA, enzyme-linked immunosorbent assay; Hb, hemoglobin; LC-ESI-MS, liquid chromatography electrospray ionization mass spectrometry; MALDI-TOF-MS, matrix-assisted laser desporption/ionization time of flight mass spectrometry; RT, room temperature; SELDI MS, surface-enhanced laser desorption/ionization mass spectrometry; TBD, to be defined; WBC, white blood cell.

###### 

[QC Measurands for Qualification of Tissue Biospecimens and Their Derivatives]{.smallcaps}

  *Biospecimen type*     *Qualification parameter*     *Measurand*               *Scope of qualification*   *Measurement method*
  ---------------------- ----------------------------- ------------------------- -------------------------- ------------------------------------
  Frozen tissue          Freeze--thaw                  Cell lysis                IHC, RNA-based analyses    H&E staining
  Viable frozen tissue   Sterility                     Absence of contaminants   Tissue culture             Growth on agar; mycoplasma testing
                         Cryopreservation conditions   Post-thaw viability                                  Growth in flasks

H&E, hematoxylin and eosin.

###### 

[QC Measurands for Quality Stratification of Tissue Biospecimens and Their Derivatives]{.smallcaps}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Biospecimen type*       *Quality stratification parameter*                            *Quality stratification parameter category*   *Measurand*                                        *Quality stratification threshold*   *Measurement method and reference*
  ------------------------ ------------------------------------------------------------- --------------------------------------------- -------------------------------------------------- ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tumor                    \% tumor                                                      Tumor-rich                                    Tumor                                              \>70%                                H&E staining, digital pathology

  FFPE                     Fixation time NBF                                             \>72 h                                        None to date^[a](#tf9){ref-type="table-fn"}^       TBD                                  qRT PCR

                           Fixation conditions                                           NBF (no acidic formalin)                      Size range RT PCR                                  ∼250 bp                              RT PCR

                           Cold ischemia                                                 \>12 h                                        None to date^[a](#tf9){ref-type="table-fn"}^       TBD                                  qRT PCR

  Frozen tissue            Cold ischemia                                                 \>12 h                                        None to date^[a](#tf9){ref-type="table-fn"}^       TBD                                  qRT PCR

  FFPE DNA                 Fixation conditions (cross-linking); extraction efficiency\   Highly deaminated                             qPCR ΔCt                                           ΔCt ≥1.55                            Illumina FFPE QC kit\
                           DNA integrity                                                                                                                                                                                       Agilent NGS FFPE QC kit\
                                                                                                                                                                                                                               or equivalent^[@B42]^

                                                                                         CGH compatible\                               PCR amplicon size                                  ≥200bp,\                             Multiplex PCR^[@B43],[@B44]^
                                                                                         WGA compatible                                                                                   ≥300 bp                              

                                                                                         Of good integrity                             WGA score                                          ≥3 μg yield                          WGA ([www.enzolifesciences.com/ENZ-42440/bioscore-screening-and-amplification-kit-20-reactions](www.enzolifesciences.com/ENZ-42440/bioscore-screening-and-amplification-kit-20-reactions))

                                                                                         Of good integrity                             DIN                                                \>7                                  Microfluidic electrophoresis

  FFPE RNA                 mRNA integrity                                                Extremely 5′ degraded                         mRNA index                                         \|ΔCt\|\>8                           qRT PCR^[@B31]^

                                                                                         Of good mRNA integrity                        Size range RT PCR                                  ∼250 bp                              RT PCR

                           Fixation time                                                 \>72 h                                        Gene targets^[a](#tf9){ref-type="table-fn"}^       TBD                                  qRT PCR

                           Ischemia time                                                 \>12 h                                        Gene targets^[a](#tf9){ref-type="table-fn"}^       TBD                                  qRT PCR

  FFPE proteins            Ischemia time                                                 TBD                                           Phospho-Tyrosine (P Tyr 100)                       TBD                                  IHC^[@B45]^

  Frozen tissue DNA        Processing/storage conditions; extraction efficiency          With no strand breaks                         Long range PCR                                     15 kb                                PCR

  Frozen tissue RNA        Processing/storage conditions; extraction efficiency\         Of high integrity                             RIN\                                               \>6                                  Microfluidic electrophoresis\
                           rRNA integrity                                                                                              RIS\                                                                                    ([www.agilent.com/cs/library/applications/5989-1165EN.pdf](www.agilent.com/cs/library/applications/5989-1165EN.pdf)), ([www.qiagen.com/gb/shop/automated-solutions/dna-analysis/qiaxcel-advanced-system/](www.qiagen.com/gb/shop/automated-solutions/dna-analysis/qiaxcel-advanced-system/)), ([www.aati-us.com/product/fragment-analyzer/download_dv200_metric](www.aati-us.com/product/fragment-analyzer/download_dv200_metric))
                                                                                                                                       DV200\                                                                                  
                                                                                                                                       or equivalent                                                                           

                           mRNA integrity                                                Not 5′ degraded                               mRNA index                                         \|ΔCt\|\<1                           qRT PCR^[@B31]^

                           Purity                                                        Not protein contaminated                      A260/A280 ratio                                    \>1.6                                Spectrophotometry

  Frozen tissue proteins   Postmortem interval/ischemia                                  \>48 h cold ischemia                          αII spectrin cleavage (no 285 kDa, only 150 kDa)   285 kDa \>150 kDa                    Western blot^[@B46]^
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Under investigation by the ISBER Biospecimen Science Working Group.

FFPE, formalin-fixed, paraffin-embedded; NBF, normal buffered formalin.

[Table 2](#T2){ref-type="table"} includes information on QC measurands for qualification for use of samples in specific disease areas.^[@B4],[@B5]^ The measurands in this table are molecules that are recognized biomarkers in the respective disease areas and are also known to be labile. Detection of the measurand above the method\'s level of detection is necessary (though not always sufficient) for qualification of a sample. As an example for reading [Table 2](#T2){ref-type="table"}, if Aβ42 is undetectable in CSF samples, then these samples cannot be qualified for research in the area of neurodegenerative diseases.

[Tables 3](#T3){ref-type="table"}, [5](#T5){ref-type="table"}, and [7](#T7){ref-type="table"} include information that can be used for the qualification of fluid, tissue, or cytological specimens, respectively, in the scope of different types of downstream analyses. In these tables, "qualification parameter" is the quality aspect of the biospecimen that is being evaluated; "measurand" is the molecule, or the morphological or functional characteristic that is being measured and whose positive or negative result is necessary for the qualification; "scope of qualification" is the type of downstream analysis for which the biospecimen is being qualified as fit-for-purpose; and "measurement method" is the type of method that is used to measure the measurand.

###### 

[QC Measurands for Qualification of Cytological Biospecimens]{.smallcaps}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Biospecimen type*                *Qualification parameter*   *Measurand*                                  *Scope of qualification*          *Measurement method*
  --------------------------------- --------------------------- -------------------------------------------- --------------------------------- ----------------------------------------------------------------------------------------------------
  All cell suspensions              Sterility                   Absence of contaminants                      Culture                           Growth on agar; mycoplasma testing

                                    Identity                    Protein markers\                             Any type of downstream analysis   ICC, ELISA, FC\
                                                                Genetic identity                                                               PCR, STR genotyping, FISH, karyology

                                    Purity                      Absence of protein markers\                  Any type of downstream analysis   ICC, ELISA, FC\
                                                                Absence of cellular impurities                                                 FC

                                    Genomic stability           Chromosomal stability\                       Any type of downstream analysis   G-banding, ICC, FC, microscopy
                                                                Phenotypic stability                                                           

  Cell line                         Identity                    STR, karyotype, SNP fingerprint^[@B47]^      Any type of downstream analysis   PCR, karyology/FISH, sequencing/arrays

  Stem cells                        Sterility                   Absence of contaminants                      Culture, functional assays        Growth on agar; mycoplasma testing, HIV, HBV, HCV, EBV, CMV, syphilis, fungus, bacteria, endotoxin

                                    Normal karyotype            Karyotype                                    Any type of downstream analysis   G-banding

                                    Identity matching           Match parent cells                           Any type of downstream analysis   STR

                                    Non oncogenicity            C-Myc, P53, p21, p16 absence of expression   Any type of downstream analysis   Immunostaining, gene expression

  Lymphoblastoid cell lines (LCL)   Normal karyotype            Karyotype                                    Any type of downstream analysis   G-banding

                                    EBV transformation          EBV gene expression                          Any type of downstream analysis   RT PCR^[@B48]^

  Circulating tumor cells (CTC)     Cancer phenotype            EpCam+, CK8+, 18+, 19+, CD45--               Any type of downstream analysis   Immunostaining^[@B49]^
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CMV, cytomegalovirus; FC, flow cytometry; FISH, fluorescent in situ hybridization; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; ICC, immunocytochemistry; SNP, single nucleotide polymorphism; STR, short tandem repeats.

[Tables 4](#T4){ref-type="table"}, [6](#T6){ref-type="table"}, and [8](#T8){ref-type="table"} include information that can be used for the quality stratification of a fluid, tissue, or cytological biospecimen, respectively. In these tables, "qualification parameter" is the quality aspect of the biospecimen for which the biospecimen is being stratified; "measurand" is the molecule, or the morphological or functional characteristic that is being measured and whose level is used to stratify the biospecimens in categories; "quality stratification thresholds" are the levels of the measurand, which are critical for the quality stratification; and "measurement method" is the type of method that is used to measure the measurand. The quality stratification thresholds listed in [Tables 4](#T4){ref-type="table"}, [6](#T6){ref-type="table"}, and [8](#T8){ref-type="table"} classify the biospecimens into the categories of the qualification parameter given. The "time xxx/temperature yyy" categories correspond to available experimental data, but they should be understood as "time xxx/temperature yyy or equivalent conditions." The quality stratification thresholds listed in [Tables 4](#T4){ref-type="table"}, [6](#T6){ref-type="table"}, and [8](#T8){ref-type="table"} are those corresponding to the measurement methods described in the references. Application of a threshold with a measurement method that is different from the method that has been used for the establishment of the threshold requires previous demonstration of the commutability of the methods.

###### 

[QC Measurands for Quality Stratification of Cytological Biospecimens]{.smallcaps}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Biospecimen type*                           *Quality stratification parameter*                *Quality stratification parameter category*   *Measurand*                                                                                                                                                                          *Quality stratification threshold*                              *Measurement method and reference*
  -------------------------------------------- ------------------------------------------------- --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------- ---------------------------------------------------------------------------
  Peripheral blood mononuclear cells (PBMCs)   Cryopreservation                                  Of high viability                             Post thaw viability                                                                                                                                                                  \>80%                                                           FC; trypan blue

                                               Specificity (granulocyte contamination)           \<12--14 h RT post venipuncture;\             CD15+ granulocytes                                                                                                                                                                   \<20%                                                           FC^[@B50]^
                                                                                                 With no T-cell function inhibition                                                                                                                                                                                                                                                                 

  All cell suspensions                         Biological activity                               Cell type specific                            Receptors\                                                                                                                                                                           Cell type-specific                                              ICC, FC, microscopy, FRET microscopy, ELISA, qRT PCR, microarray\
                                                                                                                                               Secreted proteins\                                                                                                                                                                                                                                   Dunn, Boyden or Impedance Chamber, Scratch assay, Matrigel invasion assay
                                                                                                                                               mRNA expression\                                                                                                                                                                                                                                     
                                                                                                                                               Migration                                                                                                                                                                                                                                            

                                               Concentration, viability                          Of high viability                             Cell number\                                                                                                                                                                         \>80%                                                           FC, impedance, microscopy\
                                                                                                                                               Viability                                                                                                                                                                                                                                            Viability assays

  Sperm                                        DNA integrity                                     Of compromised DNA integrity                  Acridine Orange staining and acid-induced denaturation                                                                                                                               COMPa~t~^[a](#tf12){ref-type="table-fn"}^ \>30%                 Sperm chromatin structure assay^[@B51]^

  Viable RBC                                   Storage lesion                                    \>4 days 4°C                                  2,3-diphosphoglycerate (2,3-DPG)                                                                                                                                                     \<2 mmol/L                                                      Spectrophotometry (340 nm)^[@B52]^

  Viable platelets                             Activation                                        With highly activated platelets               Surface P selectin (CD62)                                                                                                                                                            \>70%                                                           Flow cytometry^[@B53]^

  Stem cells                                   Cryopreservation conditions                       Efficiently cryopreserved                     Colony formation and diameter doubling                                                                                                                                               \<5 days                                                        Colony doubling

                                               Surface antigen expression of stem cell markers   Stem cell positive                            expression SSEA-4, expression SSEA-1                                                                                                                                                 \>80%, \<20%                                                    Immunostaining

                                               Pluripotency                                      Pluripotent                                   Upregulation of genes associated with each of the three germ layers                                                                                                                  2-fold compared to control (at least one gene per germ layer)   qRT PCR

  Liquid biopsy-based cytology specimens       Cell concentration                                *Downstream application-specific*             Number of cells                                                                                                                                                                      *Downstream application-specific*                               Cell count

  Sorted cells                                 Purity                                            Pure                                          \% of cells with expected immunophenotype, e.g., T cells (CD3), NK cells (CD16/56), B cells (CD19/20), monocytes (CD14), functional memory B cells (CD19, CD27, CD45, CD38, CD138)   \>90%                                                           Flow cytometry
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

COMP, cells outside the main population.

FRET, fluorescence resonance energy transfer; RBC, red blood cell; SSEA, stage-specific embryonic antigen.

Tissue type specificities {#s004}
-------------------------

Assays for tissue qualification or quality stratification may be tissue type--specific. Some examples are given below. Fixation conditions have a significant impact on P-Akt and P-Erk1/2 in breast cancer tissue.^[@B35]^ Ischemia has a significant impact on estrogen and progesterone receptors in breast tissue.^[@B36],[@B37]^ A Tissue Quality Index has been proposed for formalin-fixed, paraffin-embedded breast tissue in order to assess its cold ischemia time by immunohistochemistry.^[@B38]^ Stathmin^[@B2]^ has been proposed as indicator of degradation in brain tissue by matrix-assisted laser desorption/ionization time of flight mass spectrometry.^[@B39]^ AKT-P has been proposed as indicator of postmortem conditions in brain tissue by western blot.^[@B40]^ Superoxide dismutase in the liver and peptidyl-prolyl-cis-trans isomerase and insulin C-peptides in the pancreas have been associated with postmortem delay and assessed by two-dimensional difference in gel electrophoresis.^[@B41]^

Discussion {#s005}
==========

This article proposes a biospecimen QC strategy, based on current state of knowledge, in the form of summary tables ([Fig. 2](#f2){ref-type="fig"}).

![Decision tree for any given specimen type.](fig-2){#f2}

The qualification and quality stratification assays presented in this technical report do not aim for an absolute assessment of the quality of samples, since a sample can be of high enough quality (fit-for-purpose) for one type of analysis (e.g., antibody analysis), but not for other types of analyses (e.g., metabolite analysis). Therefore, scientists should devote time and effort to understand and define what sample quality is needed to obtain consistent results with a given downstream analytical platform. As can be seen from [Tables 3](#T3){ref-type="table"}, [5](#T5){ref-type="table"}, and [7](#T7){ref-type="table"}, there are several gaps in the area of biospecimen qualification for use on specific analytical platforms. These include, for example, urine, saliva, or frozen tissue qualification for use in proteomic analyses, serum, plasma, or other body fluid qualification for use in miRNome analyses, or DNA qualification for use in methylation analyses. In the absence of such knowledge, this technical report offers a strategy for sample quality stratification so that bias due to samples of inconsistent quality levels can be minimized.

The information provided in this report is important because its application will enable and support bioprocessing method validation by providing relevant readouts (measurands); assessment of the quality of biospecimens of unknown history; biomarker discovery by ensuring use of qualified biospecimens or biospecimens belonging to a specific quality category; validation of biomarker robustness by using quality-stratified biospecimens belonging to different, defined quality categories; implementation of novel biomarkers in clinical practice; and characterization and production of clinical reference materials.

For the above purposes, QC measurands of clinical biospecimens can be assessed either by the biobanks themselves, or by subcontractors/collaborators who are accredited or successfully participate in relevant Proficiency Testing schemes. The results of the QC can be used by biobanks for qualification of legacy collections (the definition of cutoff values for acceptance of legacy collections or specific samples can be made and disclosed by the biobank), by end users for stratification of samples of different origins, or by funding agencies for assessment of the fitness for purpose of collections to be used in the context of grant allocation.
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